Glucose control in UKPDS type 2 diabetic patients with and without autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase.

Eitemau Tebyg

• UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes
  gan: Turner, R, et al.
  Cyhoeddwyd: (1997)
• UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group.
  gan: Turner, R, et al.
  Cyhoeddwyd: (1997)
• Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70).
  gan: Davis, T, et al.
  Cyhoeddwyd: (2005)
• Relationship of autoantibodies to glutamic acid decarboxylase (GADA) to deterioration of glycamic control assessed by therapy progression in latent autoimmune diabetes in adults (LADA) in the UKPDS
  gan: Clark, A, et al.
  Cyhoeddwyd: (2005)
• Plasma lipids and hypoglycaemic therapies over 6 years in Type 2 diabetic patients in the UKPDS
  gan: Cull, C, et al.
  Cyhoeddwyd: (1999)